Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - Pharmaceutical Development - March 24, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/16 - ABIVAX reports on ABX464 as HIV functional cure and treatment for inflammatory diseases
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Paris, 8 December 2016- ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral disease, announced that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/A
12/31/16 - Castle Creek Pharmaceuticals Announces License of Exclusive U.S. Rights for Arlevert from Hennig Arzneimittel GmbH
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
12/31/16 - Ebola vaccine shows promise An experimental vaccine against Ebola is 100 percent effective in clinical trials
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
12/31/16 - Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial [Saudi Press Agency (Saudi Arabia)]
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
Pharmaceutical company Lupin has received tentative approval from the United States Food and Drug Administration to market its cholesterol lowering Pitavastatin tablets in the American market. has received approval for Pitavastatin tablets in the strength of 1 milligram, 2 mg and 4 mg. Pitavastatin is a generic version of Kowa's Livalo tablets in t
12/31/16 - New Chinese Ebola vaccine safe, protective: China [Press TV (Iran)]
This file photo taken on March 10, 2015, shows a woman getting vaccinated at a health center in Conakry, Guinea, during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. China says its first domestically-developed Ebola vaccine is a major medical breakthrough as it passed the Phase-II clinical test and gains permission for
12/31/16 - Pharmacist: New medications help with dry eyes, seizures and hallucinations
In 2016, many new and useful medications got FDA approval. My articles are syndicated worldwide, but I'm only listing English drug names so please ask your local pharmacist to translate the medication name for your country. So the FDA approved this injectable drug to help people who have been exposed from infected animals, contaimated animal produc
12/30/16 - 18 Stocks Moving In Friday's Pre-Market Session
Gainers Marinus Pharmaceuticals Inc rose 29.3 percent to $1.080 in pre-market trading as the company disclosed that ganaxolone has received Orphan Drug designation for the treatment of Fragile X Syndrome. China Cord Blood Corp shares rose 16.1 percent to $6.35 in pre-market trading after Golden Meditech agreed to sell its equity interest in China C
12/30/16 - Acerus Announces NATESTO License Agreement with Hyundai Pharm
By a News Reporter-Staff News Editor at Health& Medicine Week Acerus Pharmaceuticals Corporation announced the signing of an agreement granting the exclusive right to market NATESTO in South Korea to Hyundai Pharm Co., LTD., a South Korean pharmaceutical company. "Hyundai has a proven track record of success in launching products, building ne
12/30/16 - amcure Raises ?6 Million in Series B Financing and Expands Advisory Board
By a News Reporter-Staff News Editor at Drug Week amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, announced the closing of a Series B financing round amounting to a total of EUR 6 million. The financing comes from a consortium of existing investors and shareholders headed by LBBW Venture Capital, with participat
12/30/16 - Aurobindo Pharma gets US FDA approval for 2 drugs, stocks up 3% [India Infoline News Service]
Aurobindo Pharma has received US Food and Drug Administration's approval for two of its generic drugs, following which the company stocks gained positive traction. Aurobindo Pharma has received US Food and Drug Administration's approval for two of its generic drugs, following which the company stocks gained positive traction. Aurobindo Pharma Ltd i
12/30/16 - Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer [Seven Days (United Arab Emirates)]
COPENHAGEN, Denmark, December 29, 2016- Bavarian Nordic A/S today announced the initiation of a clinical trial combining its proprietary cancer immunotherapy candidate, CV301, with the anti-PD-1 drug, OPDIVO from Bristol-Myers Squibb. "We are pleased to announce the initiation of this study, which marks the entry for Bavarian Nordic into lung canc
12/30/16 - BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317
BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of the first patient in a Phase I clinical trial of BGB-A317, an anti-PD-1 monoclonal antibody, in mainland Chinese patients with advanced solid tumors.. We are enthusiastic ab
12/30/16 - Cempra shares plummet after drug fails to win approval [The News & Observer (Raleigh, N.C.)]
Dec. 29 Shares of Chapel Hill drug developer Cempra plummeted 57 percent Thursday after the company reported that the Food and Drug Administration declined to approve its experimental antibiotic. The FDA also informed the company that, although it reserves comment on drug labeling pending further tests, the risk of liver damage to patients is suc
12/30/16 - Christopher Nowinski Joins Oxeia Biopharmaceuticals Advisory Board
By a News Reporter-Staff News Editor at Energy Weekly News- Oxeia Biopharmaceuticals, Inc., a biotechnology company leading the industry in the development of first-in-class neurometabolic treatments for concussions and brain injury, announced that Christopher Nowinski, co-founder and CEO of the Concussion Legacy Foundation, has joined the compan
12/30/16 - FDA Issues Rule for Withdrawal of Approval of New Animal Drug Applications
WASHINGTON, Dec. 30 The Food and Drug Administration published the following rule in the Federal Register:. A Rule by the Food and Drug Administration on 12/27/2016. Agencies: Food and Drug Administration.
12/30/16 - IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amphastar Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Khang& Khang LLP announces that it is investigating claims against Amphastar Pharmaceuticals, Inc. concerning possible violations of federal securities laws. Amphastar announced that its company Armstrong Pharmaceuticals, Inc. received notice from the U.S. Food and Drug Administration, revealing to Armstrong that its New Drug Application for...
12/30/16 - Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease
Incyte Corporation today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease. The U.S. Food and Drug Administration has granted ruxolitinib Breakthrough Therapy...
12/30/16 - Innocoll Holdings (INNL) Tumbles on FDA Quandary
Innocoll Holdings PLC shares tumbled 65% to 62 cents, after the company received a Refusal to File letter from the FDA related to XARACOLL New Drug Application.
12/30/16 - Intellipharmaceutics to Present at the Biotech Showcase [Daily Star, The (Lebanon)]
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the annual Biotech ShowcaseTM conference on January 11, 2017.
12/30/16 - New Findings on Radius Fracture from Anjo-Kosei Hospital Summarized (Clinical effects of internal fixation for ulnar styloid fractures associated...
By a News Reporter-Staff News Editor at Health& Medicine Week Current study results on Radius Fracture have been published. According to news reporting from Anjo, Japan, by NewsRx journalists, research stated, "Ulnar styloid fractures are often associated with distal radius fractures. The news correspondents obtained a quote from the research fro
12/30/16 - Pharmaceuticals Newsletter - December 26 to 30, 2016 [India Infoline News Service]
This week, Lupin received tentative approval for generic Giazo Tablets, Aurobindo Pharma got US FDA approval for 2 drugs and Glenmark Pharma gets USFDA approval for Tretinoin Capsules. Lupin receives tentative approval for generic Giazo Tablets Pharma Major Lupin Limited announced that it has received tentative approval for its Balasalazide Disodiu
12/30/16 - PPD Expands Stability Storage and Sample Distribution at Wisconsin GMP Lab
By a News Reporter-Staff News Editor at Drug Week Pharmaceutical Product Development LLC has expanded its stability sample storage capacity and capabilities as part of its ongoing efforts to meet the growing needs of its biopharmaceutical clients. "The expansion of our stability chamber capabilities in Middleton is indicative of PPD's ongoing ef
12/30/16 - RTP-based curasan poised for growth [Tripoli Post, The (Libya)]
The FDA approval of CERASORB Ortho FOAM is an extremely important milestone for us in the re-orientation of our U.S. business, which will open up a potential market worth more than$ 900 million, said Michael Schlenk, CEO of curasan AG. curasan Inc. was established in the Triangle in 2004 and was subsequently purchased by RIEMSER Inc., a dental supp
12/30/16 - SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Innocoll Holdings, plc (INNL)
Attorney Advertising Bronstein, Gewirtz& Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Innocoll Holdings, plc. On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the U.S. Food& Drug Administration regarding its New Drug Application for XARACOLL, a postsurgica
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement